Department of Medical and Molecular Genetics
Dr. Meyer received his bachelor’s degree from Colgate University and his doctoral degree from the University of Missouri. He completed his postdoctoral training at the University of Wisconsin and was later promoted to the rank of assistant scientist, where he developed the foundational ability to differentiate human pluripotent stem cells into retinal neurons. He is currently an Associate Professor of Medical and Molecular Genetics at Indiana University School of Medicine, with adjunct appointments in Ophthalmology and the Stark Neurosciences Research Institute. His research focuses upon the differentiation of retinal ganglion cells from human pluripotent stem cells, including the derivation of glaucoma models through iPS cell reprogramming as well as Crispr/Cas9 gene editing. Ongoing projects in his lab explore the use of these cells for studies of RGC development as well as mechanisms underlying glaucomatous neurodegeneration.
Associate Professor of Medical & Molecular Genetics
Adjunct Associate Professor of Ophthalmology
Adjunct Associate Professor of Pharmacology & Toxicology
2004PhDUniversity of Missouri
Induced pluripotent stem (iPS) cells are derived through the genetic reprogramming of somatic cells to yield a population of stem cells capable of giving rise to all cell types of the body. As such, they can be utilized to study some of the earliest events underlying the generationof specific cell types of the nervous system. Current research in the lab focuses upon the differentiation of iPS cells into retinal neurons, with important implications for the study of blinding neurodegenerative diseases. Through the derivation of iPS cells from the somatic cells of patients with known genetic mutations underlying neurodegenerative diseases, it is possible to study the onset and progression of these diseases in the particular cell types affected by the disorder. Such an approach also allows for the development of personalized medicine approaches to treating diseases, as well as pharmacological screening with the goal of identifying novel compounds capable of treating these diseases.